HALOZYME THERAPEUTICS, INC. 10-Q

Item 5. Other Information None. 58 Item 6. Exhibits 3.1 Amended and Restated Certificate of Incorporation (1) 3.2 Bylaws, as amended (2) 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended 32 Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS Instance Document - the instance document does not appear in the interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH Inline Taxonomy Extension Schema Document. 101.CAL Inline Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline Taxonomy Extension Definition Linkbase Document. 101.LAB Inline Taxonomy Extension Label Linkbase Document. 101.PRE Inline Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101) (1) Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed May 3, 2019. (2) Incorporated by reference to the Registrant’s Current Report on Form 8-K, filed December 19, 2016. 59 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Halozyme Therapeutics, Inc., a Delaware corporation Dated: November 2, 2020 /s/ Helen I. Torley, M.B. Ch.B., M.R.C.P. Helen I. Torley, M.B. Ch.B., M.R.C.P. President and Chief Executive Officer (Principal Executive Officer) Dated: November 2, 2020 /s/ Elaine Sun Elaine Sun Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) 60